Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Apr 18, 2018

Overview : Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. The SECURE-PCI Randomized Clinical Trial   Trial References Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin... more

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Sep 06, 2017

Overview : Trial Reference Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas,... more

ODYSSEY Long Term Study

Oct 15, 2014

Overview : The Odyssey Long Term Study evaluated the safety and efficacy of alirocumab (mAb anti-PCSK9) in 2341 patients with heterozygous FH or at high risk for cardiovascular events who were receiving a maximally tolerated dose of statin but who had an... more

: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Oct 15, 2014

Overview : The the novel agent LCZ696 (Novartis) that has effects both within and beyond the renin-angiotensin system, was tested against of the ACE inhibitor enalapril, showing fewer HF hospitalizations and mortality from cardiovascular causes, acccording a phase 3 trial PARADIGM-HF. In... more

STREAM-Strategic Reperfusion With Tenecteplase and Antithrombotic Treatment Early After Myocardial Infarction

Jul 17, 2014

Overview : This trial confirmed that fibrinolysis with tenecteplase and contemporary antithrombotic therapy given before transport to a PCI-capable hospital, coupled with timely coronary angiography, is as effective as primary PCI in STEMI patients presenting within 3 hours of symptom onset who... more

RELAX TRIAL: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Jul 17, 2014

Overview : RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or... more

PARAMOUNT: Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction

Jul 17, 2014

Overview : The result showed that levels of NT-proBNP dropped 23% (p=0.005) over 12 weeks but only by 15% (p=0.20) over 36 weeks among those receiving LCZ696 compared with valsartan. LCZ696 was effective for the primary [natriuretic-peptide] end point in every single... more

LAPLACE-2 TRIAL

Jul 17, 2014

Overview : This is the (proprotein convertase subtilisin-kexin type 9) PCSK9 monoclonal-antibody inhibitor that increases the ability of the liver to clear low-density-lipoprotein cholesterol (LDL-C). According to results of the LAPLACE-2 trial -presented on March 30 during the ACC 2014 in Washington,... more

Page: